Has Nandini Ignatius, MD received payments from drug or device companies?

Yes. Drug and device makers reported $141,197 in general payments to Nandini Ignatius, MD across 650 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nandini Ignatius, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nandini Ignatius, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nandini Ignatius, MD

Hematology & Oncology · Newark, NJNPI 1235462128

Payments from drug & device makers

$141,197in general payments, 2019–2025

Across 650 payments — averaging $217.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$76K
Radius Health, Inc.$16K
Epizyme, Inc.$15K
E.r. Squibb & Sons, L.L.C.$15K
Incyte Corporation$9K
Daiichi Sankyo Inc.$2K
plus $8K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	26	$76,357
Radius Health, Inc.	15	$15,675
Epizyme, Inc.	6	$15,160
E.r. Squibb & Sons, L.L.C.	68	$14,599
Incyte Corporation	24	$9,100
Daiichi Sankyo Inc.	15	$2,246
Novartis	69	$966
Johnson & Johnson(2 entities)	24	$487
Sanofi	19	$424
Bristol Myers Squibb	33	$397
Merck	24	$382
Eisai Inc.	24	$369
Seagen Inc.	23	$327
Amgen(2 entities)	21	$314
Gilead(2 entities)	17	$314
Pfizer	22	$310
Bayer	16	$305
Astellas Pharma US Inc	17	$255
Lilly USA, LLC	15	$211
AbbVie	14	$193
Puma Biotechnology, Inc.	12	$182
Stemline Therapeutics Inc.	4	$163
Takeda Pharmaceuticals U.S.A., Inc.	7	$133
EMD Serono, Inc.	4	$131
GSK	8	$118
Array Biopharma Inc	7	$108
Genentech USA, Inc.	7	$107
Boehringer Ingelheim	6	$84
Pharmacosmos Therapeutics Inc.	4	$77
Kyowa Kirin, Inc.	5	$75
Taiho Oncology, Inc.	4	$72
Coherus Oncology, Inc.	4	$71
Adaptive Biotechnologies Corporation	2	$60
AVEO Pharmaceuticals, Inc.	2	$60
Pharmacyclics LLC, An Abbvie Company	4	$59
Jazz Pharmaceuticals Inc.	4	$57
GE HealthCare	1	$56
Servier Pharmaceuticals LLC	3	$54
G1 Therapeutics, Inc.	3	$52
Rigel Pharmaceuticals, Inc.	3	$51
Genmab U.S., Inc.	3	$49
Exelixis Inc.	3	$49
Mirati Therapeutics, Inc.	3	$48
Sobi, Inc	3	$47
Myovant Sciences Inc.	3	$46
Ipsen Biopharmaceuticals, Inc	3	$46
Blueprint Medicines Corporation	3	$43
Myriad Genetic Laboratories, Inc.	1	$38
Springworks Therapeutics, Inc.	2	$38
Beigene USA, Inc.	3	$38
Azurity Pharmaceuticals, Inc.	2	$34
Apellis Pharmaceuticals, Inc.	2	$34
Pharmaessentia USA Corporation	2	$33
Octapharma USA, Inc.	2	$32
Karyopharm Therapeutics Inc.	2	$32
Foundation Medicine, Inc.	2	$30
Dendreon Pharmaceuticals LLC	1	$29
Morphosys, US Inc.	2	$29
Acceleron Pharma, Inc.	2	$28
Regeneron Healthcare Solutions, Inc.	2	$28

How this compares

$141,197 in reported general payments places this provider in the 80th percentile of 362 hematology & oncology providers in New Jersey.

See all hematology & oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024

$1,614,239

Medicare patients

635

Services billed

99,800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Newark

Anupama NehraNewark$925K
Sharon LiNewark$177K
Bruno FangEast Brunswick$8.5M
Charles FarberMorristown$4.6M
Rajat BannerjiNew Brunswick$3.3M
Eleonora TeplinskyParamus$2.6M
Mohamad CherryMorristown$1.9M
Evan NaylorManahawkin$1.3M
James OrsiniBelleville$1.3M
Eli KirshnerWestwood$1.2M

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →